Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Opposing effects of mutant ras oncoprotein on human fibroblast and epithelial cell proliferation: implications for models of human tumorigenesis

Abstract

Using microinjection of recombinant protein to directly control ‘expression’ levels, we have compared the proliferative response to ras oncogene activation in two normal cell types – fibroblast and thyroid epithelial cell – which give rise to human tumours with very low and high frequencies of ras mutation respectively. A concentration-dependent stimulation of DNA synthesis was observed in thyrocytes, matched by an almost perfectly reciprocal inhibition in fibroblasts. A concentration-dependent induction of the cyclin-dependent kinase (CDK) inhibitor p21WAF1 was observed in both cell types, but p16Ink4a was induced by ras only in fibroblasts. This difference could not account for the fibroblast specificity of the growth-inhibitory response, however, since proliferation of p16-deficient fibroblasts was also inhibited by mutant ras. We conclude that the striking contrast in proliferative response to ras between fibroblasts and thyroid epithelial cells cannot readily be explained by differential induction of either of the two key CDK inhibitors, p16Ink4a and p21WAF1, but is consistent with a differential ability of p21WAF1 to antagonize ras-induced mitogenic signals in the two cell types. Such tissue-specific differences provide an attractive explanation for the observed specificity of ras mutation for particular human tumour types, and emphasize the inappropriateness of fibroblasts as a model for ras-induced tumorigenesis.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N and Perucho M . (1988). Cell, 53, 549–554.

  • Bond JA, Wyllie FS, Rowson J, Radulescu A and Wynford-Thomas D . (1994). Oncogene, 9, 281–290.

  • Bos JL . (1989). Cancer Res., 49, 4682–4689.

  • Bredel M and Pollack IF . (1999). Brain Res. Rev., 29, 232–249.

  • Brookes S, Rowe J, Ruas M, Llanos S, Clark PA, Lomax M, James MC, Vatcheva R, Bates S, Vousden KH, Parry D, Gruis N, Smit N, Bergman W and Peters G . (2002). EMBO J., 21, 2936–2945.

  • Campbell C, Quinn AG and Rees JL . (1993). Br. J. Dermatol., 128, 111–114.

  • Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC and Weinberg RA . (2001). Genes Dev., 15, 50–65.

  • Gire V and Wynford-Thomas D . (1998). Mol. Cell Biol., 18, 1611–1621.

  • Gire V, Marshall CJ and Wynford-Thomas D . (1999). Oncogene, 18, 4819–4832.

  • Gruis NA, van der Velden PA, Sandkuijl KA, Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W and Frants RR . (1995). Nat. Genet., 10, 351–353.

  • Hahn WC and Weinberg RA . (2002). Nat. Rev. Cancer, 2, 331–341.

  • Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW and Weinberg RA . (1999). Nature, 400, 464–468.

  • Jones CJ, Kipling D, Morris M, Hepburn P, Skinner J, Bounacer A, Wyllie FS, Ivan M, Bartek J, Wynford-Thomas D and Bond JA . (2000). Mol. Cell. Biol., 20, 5690–5699.

  • Lazarov M, Kubo Y, Cai T, Dajee M, Tarutani M, Lin Q, Fang M, Tao S, Green CL and Khavari PA . (2002). Nat. Med., 8, 1105–1114.

  • Lemoine NR, Mayall ES, Wyllie FS, Williams ED, Goyns M, Stringer B and Wynford-Thomas D . (1989). Oncogene, 4, 159–164.

  • Rich JN, Guo C, McLendon RE, Bigner DD, Wang XF and Counter CM . (2001). Cancer Res., 61, 3556–3560.

  • Rossig L, Jadidi AS, Urbich C, Badorff C, Zeiher AM and Dimmeler S . (2001). Mol. Cell. Biol., 21, 5644–5657.

  • Schmitt CA . (2003). Nat. Rev. Cancer, 3, 286–295.

  • Serrano M, Lin AW, McCurrach ME, Beach D and Lowe SW . (1997). Cell, 88, 593–602.

  • Suarez HG, du Villard JA, Severino M, Caillou B, Schlumberger M, Tubiana M, Parmentier C and Monier R . (1990). Oncogene, 5, 565–570.

  • von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE and Boss GR . (2000). Breast Cancer Res. Treat., 62, 51–62.

  • Wei W, Hemmer RM and Sedivy JM . (2001). Mol. Cell. Biol., 21, 6748–6757.

  • Wei W, Jobling WA, Chen W, Hahn WC and Sedivy JM . (2003). Mol. Cell. Biol., 23, 2859–2870.

  • Williams DW, Williams ED and Wynford-Thomas D . (1988). Br. J. Cancer, 57, 535–539.

  • Woods D, Parry D, Cherwinski H, Bosch E, Lees E and McMahon M . (1997). Mol. Cell. Biol., 17, 5598–5611.

  • Zhu Y and Parada LF . (2002). Nat. Rev. Cancer, 2, 616–626.

Download references

Acknowledgements

We are grateful to Dr Gordon Peters (CR-UK London Research Institute) for supply of the ‘Leiden’ p16-deficient fibroblast strain, and to Dr James Smith (Houston) for the HCA2 fibroblast strain. We thank Cancer Research UK for grant support.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David Wynford-Thomas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Skinner, J., Bounacer, A., Bond, J. et al. Opposing effects of mutant ras oncoprotein on human fibroblast and epithelial cell proliferation: implications for models of human tumorigenesis. Oncogene 23, 5994–5999 (2004). https://doi.org/10.1038/sj.onc.1207798

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207798

Keywords

This article is cited by

Search

Quick links